Prevention and treatment of amyloidogenic disease
First Claim
Patent Images
1. A composition comprising a fragment of Aβ
- (SEQ ID NO;
1) linked to a carrier molecule to form a conjugate and an adjuvant wherein the adjuvant enhances an immune response comprising antibodies to the Aβ
fragment.
7 Assignments
0 Petitions
Accused Products
Abstract
The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer'"'"'s disease. In such methods, a suitable agent is Aβ, peptide or an antibody thereto.
175 Citations
60 Claims
-
1. A composition comprising a fragment of Aβ
- (SEQ ID NO;
1) linked to a carrier molecule to form a conjugate and an adjuvant wherein the adjuvant enhances an immune response comprising antibodies to the Aβ
fragment. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10)
- (SEQ ID NO;
-
11. A method of therapeutically treating a disease characterized by an amyloid deposit of Aβ
- in a patient having the disease, comprising;
administering a fragment of Aβ
(SEQ ID NO;
1) and an adjuvant in a regime effective to induce an immune response comprising antibodies to the Aβ
fragment and thereby therapeutically treat the disease in the patient, wherein the Aβ
fragment is linked to a carrier molecule to form a conjugate, and the adjuvant enhances the immune response to the Aβ
fragment. - View Dependent Claims (12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)
- in a patient having the disease, comprising;
-
35. A method of prophylactically treating a disease characterized by an amyloid deposit of Aβ
- in a patient susceptible to the disease, comprising;
administering a fragment of Aβ
(SEQ ID NO;
1) and an adjuvant in a regime effective to induce an immune response comprising antibodies to the Aβ
fragment and thereby prophylactically treat the disease in the patient, wherein the Aβ
fragment is linked to a carrier molecule to form a conjugate, and the adjuvant enhances the immune response to the Aβ
fragment. - View Dependent Claims (36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60)
- in a patient susceptible to the disease, comprising;
Specification